Monocyte News and Research

RSS

IDM Pharma plans to amend NDA for Mifamurtide (L-MTP-PE) for the treatment of osteosarcoma

IDM Pharma, Inc. has announced that it has recently met with the U.S. Food and Drug Administration (FDA) and informed the FDA that the Company intends to take immediate action to supplement the data in its current New Drug Application (NDA) for mifamurtide (L-MTP-PE), formerly known as Junovan, which is being reviewed for the treatment of children and adolescents with non-metastatic osteosarcoma.

23 Jul 2007

Impaired anti-inflammatory response plays role in pathology of type 2 diabetes

Type 2 diabetes is classified as a metabolic disorder, but a growing number of researchers are beginning to think of it also as a disease of the innate immune system. Inflammation, a key component of the early immune response, is chronically elevated in people with type 2 diabetes.

17 Jun 2007

Researchers discover genetic 'shut down' trigger in healthy immune cells

A fundamental genetic mechanism that shuts down an important gene in healthy immune system cells has been discovered that could one day lead to new therapies against infections, leukemia and other cancers.

10 May 2007

Shutting down microglia

Developing brain tumors can coax assistance from nearby cells known as microglia, according to a new study from scientists at Washington University School of Medicine in St. Louis. The researchers have identified one protein made by microglia that helps accelerate tumor growth and are looking for others.

15 Apr 2007

Developing brain tumors coax assistance from nearby cells

Developing brain tumors can coax assistance from nearby cells known as microglia, according to a new study from scientists at Washington University School of Medicine in St. Louis.

12 Apr 2007

Researchers find protein associated with brain cell death

Neuroscientists at the Case Western Reserve University School of Medicine have found evidence of which protein in the brain's immune cells triggers a cascade of reactions that produces unregulated free radical production that eventually leads to the neural cell death found in Alzheimer's disease.

19 Jul 2006

Functionalized carbon nanotubes are non-cytotoxic and preserve the functionality of primary immune cells

Various types of carbon-based nanomaterials, such as buckyballs and nanotubes, have shown promise as drug delivery tools and imaging agents, but reports of toxicity associated with some of these materials have raised questions about their ultimate utility in clinical oncology.

10 Jul 2006

AUA podium session on stone disease

2-phase randomized crossover study on a constant diet with calcium carbonate supplementation at 250 mg 4 times daily.

13 Jun 2006

Newly discovered gene MCPIP may lead to treatments for preventing inflammation that cause heart disease

A newly discovered gene known as MCPIP could provide scientists with the key to developing treatments for preventing inflammation that can cause heart disease, University of Central Florida researchers have discovered.

17 May 2006

Signaling pathways in immune cells may lead to novel HIV treatment

New research on signaling pathways in immune cells bolsters evidence of connections between the central nervous system and the immune system.

16 May 2006

Inflammation markers identify fatigue in breast cancer survivors

Researchers at the University of California, Los Angeles have defined conditions associated with disabling fatigue that persists for years in almost a third of breast cancer survivors, according to a study in the May 1 issue of Clinical Cancer Research.

3 May 2006

Placental growth factor may help body repair heart attack damage

Heart attack patients produce higher levels of a natural substance in the body that plays a role in the growth of new blood vessels and this over-expression of placental growth factor (PlGF) may help reduce damage to the heart muscle

17 Apr 2006

Novel approach to creating a vaccine to treat melanoma

A novel approach to creating a vaccine to treat melanoma has demonstrated promising effectiveness in a new laboratory study led by researchers at The Wistar Institute. About a third of melanoma patients might benefit from such a vaccine.

4 Apr 2006

Elastin fragments drive emphysema

Pulmonary emphysema is caused primarily by cigarette smoking, and the underlying cellular mechanisms are thought to involve smoke-induced activation of tissue degrading enzymes known as proteases.

16 Feb 2006

Source of crucial immune cell in the skin discovered - may lead to tumor immunotherapy

Mount Sinai School of Medicine researchers have identified the precursors of cells in the skin that are part of the first line of defense against invading pathogens. The study appears on Nature Immunology's website.

7 Feb 2006

Study finds short-term lifestyle changes improve health even without major weight loss

Obese and overweight individuals suffering metabolic syndrome and Type 2 diabetes showed significant health improvements after only three weeks of diet and moderate exercise even though the participants remained overweight.

10 Jan 2006

New pathways linking liver disease to changes in the central nervous system

Liver disease is often associated with "sickness behaviors," such as malaise, listlessness, anorexia, difficulty concentrating, and fatigue. In cholestatic liver diseases (where bile production is impaired) such as primary biliary cirrhosis, fatigue occurs in up to 86 percent of patients.

5 Jan 2006

Extremely infectious pneumonia-like disease slips through body's immune system

A new study found that an extremely infectious pneumonia-like disease in humans slips through the immune system's usual defense mechanisms.

21 Dec 2005

Possible toxic damage from inhaled nanoparticles

A physicist and a medical researcher at the University of Leicester have received a grant of £100,000 from the Engineering and Physical Sciences Research Council to look at possible toxic damage from inhaled nanoparticles used for a range of everyday purposes.

27 Oct 2005

Researchers successfully treat laboratory model of a lysosomal storage disease called GM1

Physicians might one day be able to treat a disease that destroys brain cells in children using genetically modified cells to transport a "drug" to the site of the dying neural cells (cells that transmit impulses).

27 Jun 2005